Lv3
242 积分 2025-05-06 加入
Clinical Outcomes in Relapsed DLBCL Patients Approved for CAR-T Therapy-A Single-Centre Study
6天前
已完结
Impact of Baseline Anxiety and Depression on Toxicity and Outcomes after Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisangenleucel for Patients with Diffuse Large B-cell Lymphoma
6天前
已完结
CLINICAL BIOMARKERS ASSOCIATED with PROGRESSION FREE SURVIVAL to CILTACABTAGENE AUTOLEUCEL in CHINESE PATIENTS with RELAPSED/REFRACTORY MULTIPLE MYELOMA from CARTIFAN-1 STUDY
8天前
已关闭
ENHANCED CAR T-CELL EXPANSION AND DURABLE COMPLETE RESPONSES WITH NKTR-255 PLUS LISOCABTAGENE MARALEUCEL IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
11天前
已关闭
Impact of Pre-Existing Neurocognitive Impairments on Toxicity and Outcomes after Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisangenleucel for Patients with Diffuse Large B-cell Lymphoma
27天前
已关闭
Real‑world efficacy of CAR T‑cell therapies: a HealthTree cure hub's study of multiple myeloma patients
27天前
已完结
Dynamic palmitoylation of STX11 controls injury-induced fatty acid uptake to promote muscle regeneration
2个月前
已完结
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management
4个月前
已完结
Chimeric antigen receptor T cell therapy for autoimmune disease
4个月前
已完结
皖公网安备34019202002308
